ATE467688T1 - Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion - Google Patents

Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion

Info

Publication number
ATE467688T1
ATE467688T1 AT07752661T AT07752661T ATE467688T1 AT E467688 T1 ATE467688 T1 AT E467688T1 AT 07752661 T AT07752661 T AT 07752661T AT 07752661 T AT07752661 T AT 07752661T AT E467688 T1 ATE467688 T1 AT E467688T1
Authority
AT
Austria
Prior art keywords
viral
antisense compound
infection
arenavirus infection
subunits
Prior art date
Application number
AT07752661T
Other languages
English (en)
Inventor
Benjamin Neuman
David Stein
Michael Buchmeier
Patrick Iversen
Original Assignee
Avi Biopharma Inc
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avi Biopharma Inc, Scripps Research Inst filed Critical Avi Biopharma Inc
Application granted granted Critical
Publication of ATE467688T1 publication Critical patent/ATE467688T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
AT07752661T 2006-03-07 2007-03-07 Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion ATE467688T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78022806P 2006-03-07 2006-03-07
PCT/US2007/005977 WO2007103529A2 (en) 2006-03-07 2007-03-07 Antisense antiviral compound and method for treating arenavirus infection

Publications (1)

Publication Number Publication Date
ATE467688T1 true ATE467688T1 (de) 2010-05-15

Family

ID=38475578

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07752661T ATE467688T1 (de) 2006-03-07 2007-03-07 Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion

Country Status (7)

Country Link
US (2) US7582615B2 (de)
EP (1) EP2002018B1 (de)
AT (1) ATE467688T1 (de)
AU (1) AU2007223776B2 (de)
CA (1) CA2644262C (de)
DE (1) DE602007006457D1 (de)
WO (1) WO2007103529A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE479763T1 (de) 2003-04-29 2010-09-15 Avi Biopharma Inc Zusammensetzungen zur verbesserung der antisense- wirksamkeit und des transports von nukleinsäureanalog in zellen
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8524676B2 (en) * 2005-09-08 2013-09-03 Sarepta Therapeutics, Inc. Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
US8871746B2 (en) * 2006-03-02 2014-10-28 Kineta Four, LLC Antiviral drugs for treatment of arenavirus infection
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
JP5864100B2 (ja) * 2007-06-29 2016-02-17 サレプタ セラピューティクス インコーポレイテッド 組織特異的ペプチドコンジュゲートおよび方法
KR101944119B1 (ko) 2009-11-13 2019-01-30 사렙타 쎄러퓨틱스 인코퍼레이티드 안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법
US9050373B2 (en) 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
KR102095478B1 (ko) 2010-05-28 2020-04-01 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
EP2672977A1 (de) 2011-02-08 2013-12-18 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Antisense-oligonukleotide
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
EP2704749A1 (de) 2011-05-05 2014-03-12 Sarepta Therapeutics, Inc. Peptid-oligonukleotidkonjugate
CA2854907C (en) 2011-11-18 2020-03-10 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
MD3554553T2 (ro) 2016-12-19 2022-10-31 Sarepta Therapeutics Inc Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
ATE124999T1 (de) 1985-03-15 1995-07-15 Antivirals Inc Immunotestmittel für polynukleotid und verfahren.
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
AU652577B2 (en) 1990-08-14 1994-09-01 Isis Pharmaceuticals, Inc. Inhibition of influenza virus type A, Ann Arbor strain H2N2 by antisense oligonucleotides
US7094765B1 (en) 1999-01-29 2006-08-22 Avi Biopharma, Inc. Antisense restenosis composition and method
KR20010102992A (ko) 1999-01-29 2001-11-17 추후보정 표적 ｒｎａ를 검출하는 비-침입적 방법
JP2003516151A (ja) 1999-11-29 2003-05-13 エイブイアイ バイオファーマ， インコーポレイテッド 細菌１６Ｓおよび２３ＳｒＲＮＡに標的化された、荷電していないアンチセンスオリゴヌクレオチド、ならびにその使用
US7049431B2 (en) 2000-01-04 2006-05-23 Avi Biopharma, Inc. Antisense antibacterial cell division composition and method
EP1282699B1 (de) 2000-05-04 2012-11-21 Sarepta Therapeutics, Inc. Spleisregion-antisensezusammensetzung und verfahren
EP1301525B1 (de) 2000-07-06 2015-09-02 Sarepta Therapeutics, Inc. Transformation einer stammzellen enthaltenden, mit einem den wachstumsfaktor beta (tgf-beta) blockierenden mittel behandelten zusammensetzung und entsprechendes verfahren dazu
AU2002362312A1 (en) * 2001-09-17 2003-04-01 Mayo Foundation For Medical Education And Research Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
EP1507791B1 (de) 2001-10-16 2013-12-18 Sarepta Therapeutics, Inc. Antisense-antivirusmittel und verfahren zur behandlung einer ssrna-virusinfektion

Also Published As

Publication number Publication date
AU2007223776A1 (en) 2007-09-13
US7582615B2 (en) 2009-09-01
CA2644262C (en) 2016-01-05
EP2002018B1 (de) 2010-05-12
US20070274957A1 (en) 2007-11-29
WO2007103529A2 (en) 2007-09-13
US7855283B2 (en) 2010-12-21
US20100063133A1 (en) 2010-03-11
WO2007103529A3 (en) 2007-12-13
CA2644262A1 (en) 2007-09-13
EP2002018A4 (de) 2009-03-25
AU2007223776B2 (en) 2014-05-22
EP2002018A2 (de) 2008-12-17
DE602007006457D1 (de) 2010-06-24

Similar Documents

Publication Publication Date Title
ATE467688T1 (de) Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion
WO2007030691A3 (en) Antisense antiviral compound and method for treating picornavirus infection
WO2007030576A3 (en) Antisense antiviral compound and method for treating picornavirus infection
WO2006047683A3 (en) Antisense antiviral compound and method for treating influenza viral infection
ATE540116T1 (de) Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionen
ATE491791T1 (de) Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen
WO2006033933A3 (en) Antisense antiviral compound and method for treating ssrna viral infection
CY1118029T1 (el) Βακτηριοφαγος ή λυτικη πρωτεϊνη που προερχεται απο το βακτηριοφαγο που ειναι αποτελεσματικα για την αντιμετωπιση βιομεμβρανης απο staphylococcus aureus
CY1121037T1 (el) Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων
CA2526893A1 (en) Inhibition of the expression of huntingtin gene
ATE550025T1 (de) Behandlung neurodegenerativer erkrankungen mittels intrakranialer freisetzung von small- interfering-rna (sirna)
WO2007044468A3 (en) Method to treat flavivirus infection with sirna
NZ591416A (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
RU2012114198A (ru) Модуляция экспрессии гентингтина
ATE460500T1 (de) Zusammensetzungen und verfahren zur sirna- inhibition der angiogenese
ATE498685T1 (de) Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
UA101806C2 (ru) Одноцепочечная кольцевая рнк и способ ее получения
BR112012011381B8 (pt) oligonucleotídeo antisenso antiviral isolado e composição farmacêutica compreendendo o mesmo
WO2015023941A1 (en) Oligonucleotides targeting euchromatin regions of genes
ATE528008T1 (de) Rnai-modulation von aha und ihre therapeutische verwendung
RU2018113276A (ru) Антисмысловая нуклеиновая кислота
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
WO2005013905A3 (en) SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION
EP1704243A4 (de) Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties